These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 19368038)
21. Psychological treatments for stimulant misuse, comparing and contrasting those for amphetamine dependence and those for cocaine dependence. Vocci FJ; Montoya ID Curr Opin Psychiatry; 2009 May; 22(3):263-8. PubMed ID: 19307968 [TBL] [Abstract][Full Text] [Related]
22. Clinical Trials for Stimulant Use Disorders: Addressing Heterogeneities That May Undermine Treatment Outcomes. Regier PS; Kampman KM; Childress AR Handb Exp Pharmacol; 2020; 258():299-322. PubMed ID: 32193666 [TBL] [Abstract][Full Text] [Related]
28. Medications for stimulant abuse: agonist-based strategies and preclinical evaluation of the mixed-action D-sub-2 partial agonist aripiprazole (Abilify). Bergman J Exp Clin Psychopharmacol; 2008 Dec; 16(6):475-83. PubMed ID: 19086768 [TBL] [Abstract][Full Text] [Related]
29. Development of vaccines to help treat drug dependence. Bunce CJ; Loudon PT; Akers C; Dobson J; Wood DM Curr Opin Mol Ther; 2003 Feb; 5(1):58-63. PubMed ID: 12669472 [TBL] [Abstract][Full Text] [Related]
30. Biotechnology and the treatment of addictive disorders: new opportunities. Elkashef A; Biswas J; Acri JB; Vocci F BioDrugs; 2007; 21(4):259-67. PubMed ID: 17628123 [TBL] [Abstract][Full Text] [Related]
31. Understanding Stimulant Use and Use Disorders in a New Era. Ciccarone D; Shoptaw S Med Clin North Am; 2022 Jan; 106(1):81-97. PubMed ID: 34823736 [TBL] [Abstract][Full Text] [Related]
32. Treatment of patients with substance use disorders, second edition. American Psychiatric Association. Kleber HD; Weiss RD; Anton RF; George TP; Greenfield SF; Kosten TR; O'Brien CP; Rounsaville BJ; Strain EC; Ziedonis DM; Hennessy G; Connery HS; McIntyre JS; Charles SC; Anzia DJ; Cook IA; Finnerty MT; Johnson BR; Nininger JE; Summergrad P; Woods SM; Yager J; Pyles R; Cross CD; Peele R; Shemo JP; Lurie L; Walker RD; Barnovitz MA; Gray SH; Saxena S; Tonnu T; Kunkle R; Albert AB; Fochtmann LJ; Hart C; Regier D; ; ; Am J Psychiatry; 2007 Apr; 164(4 Suppl):5-123. PubMed ID: 17569411 [No Abstract] [Full Text] [Related]
33. Agonist-like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies. Herin DV; Rush CR; Grabowski J Ann N Y Acad Sci; 2010 Feb; 1187():76-100. PubMed ID: 20201847 [TBL] [Abstract][Full Text] [Related]
34. Addictiveness of central stimulants. Dackis CA; Gold MS Adv Alcohol Subst Abuse; 1990; 9(1-2):9-26. PubMed ID: 1974121 [TBL] [Abstract][Full Text] [Related]
35. Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Stoops WW; Rush CR Expert Rev Clin Pharmacol; 2014 May; 7(3):363-74. PubMed ID: 24716825 [TBL] [Abstract][Full Text] [Related]
38. Effect of stimulant medications for attention-deficit/hyperactivity disorder on later substance use and the potential for stimulant misuse, abuse, and diversion. Faraone SV; Wilens TE J Clin Psychiatry; 2007; 68 Suppl 11():15-22. PubMed ID: 18307377 [TBL] [Abstract][Full Text] [Related]
39. Assessment of new medications for stimulant abuse treatment. Woolverton WL; Kleven MS NIDA Res Monogr; 1992; 119():155-9. PubMed ID: 1359417 [No Abstract] [Full Text] [Related]
40. Ethical and policy issues in using vaccines to treat and prevent cocaine and nicotine dependence. Hall W; Gartner C Curr Opin Psychiatry; 2011 May; 24(3):191-6. PubMed ID: 21430537 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]